Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Third Rock Ventures
Biotech
Schizophrenia-minded Syremis takes off with $165M series A
Founded by a team of neuropsychiatric-focused Teva alums and the force behind Cobenfy maker Karuna, Syremis touts a M1/M4 agonist and other prospects.
Zoey Becker
Dec 18, 2025 12:59pm
Biotech veteran Robert Langer joins son launching new VC
Sep 18, 2025 3:15pm
After 'complete standstill,' biotech market reaches new normal
Aug 20, 2025 11:04am
Third Rock-backed Merida unveils with $121M for autoimmune plans
Apr 8, 2025 11:03am
Marea, Ashibio, Arvinas & more—Chutes & Ladders
Jun 21, 2024 8:30am
Marea ropes in $190M for clinical-stage cardiometabolic program
Jun 18, 2024 7:00am
